A. Gaw, C.J. Packard, J. Shepherd: Fibrates. In: Schettler G., Habenicht A.J.R. (eds) Principles and Treatment of Lipoprotein Disorders. Handbook of Experimental Pharmacology, Band 109, 1994. Springer, Berlin, Heidelberg. doi:10.1007/978-3-642-78426-2_12
S. Yamashita, D. Masuda, Y. Matsuzawa:Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases. In: Current Atherosclerosis Reports. Band22, 2020, doi:10.1007/s11883-020-0823-5.
Eiichi Araki et al.:Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. In: Diabetes Care. Band41, 2018, doi:10.2337/dc17-1589.
Traugott Scheytt, Susanne Grams, Holger Fell:Vorkommen und Verhalten eines Arzneimittels (Clofibrinsäure) im Grundwasser. In: Grundwasser. Band3, Nr.2, 1.Juni 1998, S.67–77, doi:10.1007/s767-1998-8568-1.
Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau Ministry of Health, Labour and Welfare: Review report (Parmodia Tab. 0.1 mg ), 13. Juni 2017 (PDF; 672kB).